Drug Profile
Lebrikizumab - Eli Lilly and Company
Alternative Names: DRM 06; EBGLYSS; LY 3650150; MILR-1444A;; MILR1444A; MILR1444Ab; RG 3637; RO 5490255; TNX 650Latest Information Update: 13 Mar 2024
Price :
$50
*
At a glance
- Originator Tanox
- Developer Almirall S.A.; Chugai Pharmaceutical; Eli Lilly and Company; Genentech; Roche; Tanox
- Class Anti-inflammatories; Antiasthmatics; Antifibrotics; Antineoplastics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Interleukin 13 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Atopic dermatitis
- Phase III Idiopathic pulmonary fibrosis
- Discontinued Asthma; Chronic obstructive pulmonary disease; Hodgkin's disease
Most Recent Events
- 10 Mar 2024 Efficacy and adverse events data from the phase IIIb ADmirable trial in Atopic dermatitis released by Eli Lilly and Company
- 28 Feb 2024 Eli Lilly and Company plans a phase III trial for Atopic dermatitis (Combination therapy, Monotherapy) in May 2024 in China and South korea (SC) (NCT06280716)
- 19 Feb 2024 Launched for Atopic dermatitis in Germany (SC)